KH631

· Chengdu Origen Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KH631, covering 2025-12-31 to 2025-12-31. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration [Phase 1]

See pricing